Skip to content

Study of Parenteral Nutrition to Patients With Gastrointestinal Cancer

Best Nutritional Care in Cancer Patients. A Comparative Randomized Study of Supplemental Parenteral Nutrition to Patients With GI Cancer Compared to Best Supportive Nutritional Care

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02066363
Enrollment
47
Registered
2014-02-19
Start date
2014-03-01
Completion date
2017-08-30
Last updated
2017-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Body Composition, Beneficial, Cancer Cachexia, Dietary Modification, Gastrointestinal Cancer, Quality of Life

Keywords

Bioelectrical impedance, Parenteral nutrition, Malnutrition, Quality of life., Cancer cachexia, Body composition

Brief summary

Clinical background: Weight loss is a common problem in patients suffering from gastrointestinal cancer. It is demonstrated that the prognosis for cancer patients with weight loss is worse than that for weight stable patients. Malnutrition in cancer patients is associated with a poor prognosis and is an important predictor of mortality. Supplementation with home parenteral nutrition in aphagic and terminal patients has shown improved quality of life, energy balance, body composition and prolonged survival. Aim: The aim of this study is primarily to study the effects of supplementation with parenteral nutrition, to patients with advanced incurable gastrointestinal cancer on lean body-mass and body composition. Patients found to be at nutritional risk will be included in the study and will be randomized to either best supportive nutritional care or best supportive nutritional care and supplemental Parenteral Nutrition. Design: This study is a controlled, randomized trial with two parallel study arms. The study will include patients with advanced GI cancers at nutritional risk, performance status 0-2 and with an expected survival of a minimum of 3 months. A total of 100 patients are planned to be enrolled and randomized to either best supportive nutritional care or best supportive nutritional care and supplemental parenteral Nutrition. Primary endpoint is improvement of lean body mass, and by that improvement of quality of life, performance status and cancer treatment tolerance. Discussion: The planned study will provide important information about the effect of parenteral nutrition in a patient group with advanced gastrointestinal cancer. Palliative treatment strategies are set up to improve quality of life as well as prolongation of life. Parenteral nutrition in this patient group may indeed contribute to both these aspects of palliation.

Detailed description

Randomizing. The patients will be enrolled in the study, by block randomizing using a computer generated list, stratifying in respect to performance status 0 and 1 in opposite to PS 2 for the first 10 patients enrolled in the study. To make the two treatment groups comparable, the patients number 11-100 enrolled in the study will be placed in the treatment groups using the minimization method. Using the minimization method the prognostic factors for age, diagnosis and performance status at the enrollment, will be considered to make the treatment groups similar.

Interventions

DIETARY_SUPPLEMENTDietician advise

Dietician advise 5 times, during 24weeks. Prescription of a diet plan if wanted from the patient.

DIETARY_SUPPLEMENTParenteral nutrition

Supportive parenteral nutrition.

Sponsors

Baxter Healthcare Corporation
CollaboratorINDUSTRY
Region of Southern Denmark
CollaboratorOTHER
Danish Cancer Society
CollaboratorOTHER
Aase and Ejnar Danielsens Foundation
CollaboratorOTHER
Hartmann Fonden
CollaboratorOTHER
Knud and Edith Eriksen Memorial Fund
CollaboratorUNKNOWN
Merchant M. Brogaard and Wife Memorial fund
CollaboratorUNKNOWN
Odense Patient Data Explorative Network
CollaboratorOTHER
Odense University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Histologically confirmed non-resectable GI-Cancer * at nutritional risk; having lost 5% of body weight during the previous 3 months or has failed to reach intake by 25% in the last 2 weeks. * At performance status 0-2 * Life expectancy more than 3 months. * Age over 18 years old. * Able to give written consent

Exclusion criteria

* Gastrointestinal obstruction or failure. * Immune deficiency diseases (apart from the cancer disease. ) * Current infection or sepsis.

Design outcomes

Primary

MeasureTime frameDescription
Changes in body compositionSix monthsMeasured by using bioelectrical impedance analysis.

Secondary

MeasureTime frameDescription
Time to to exacerbate Quality of Lifesix monthsAssessment of quality of life by European Organization for Research and Treatment of Cancer (EORTC) Quality of life questionnaire (QLQ30)

Other

MeasureTime frameDescription
frequency of readmission to the Hospital6 monthsNumber of admissions
Survival in study6 monthsTime to event; survival time in study

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026